Tempus in the news

Eric Lefkofsky and Margaret Anderson discuss the road ahead for the health care industry. Video linked here.    

Chicago, April 29 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced a new research collaboration with the Feist-Weiller Cancer Center at LSU aimed at improving outcomes for patients battling brain cancer.   As part of this research study, Tempus...

Chicago, April 12 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data announced a new collaboration with the Huntsman Cancer Institute at the University of Utah (HCI) aimed at improving outcomes for patients diagnosed with pancreatic cancer. While personalized treatment app...

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aim...

December 19 – Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an expansion of its biological modeling work to include profiling therapeutic responses across hundreds of unique patient derived organoid models. Tempus has been working with researchers...

Eric Lefkofsky and Max Chafkin discuss data-driven medicine. Video linked here.  

Dec 03, 2018 | Neil Versel  CHICAGO (GenomeWeb) – Having raised some $320 million in funding since its launch in 2015, cancer informatics and precision medicine company Tempus continues to ramp up its clinical and molecular data collection and curation to support precision oncology, and is beginning to turn its attention to other disease areas. In Septembe...

Eric Lefkofsky and Dr. James Hamblin discuss using big data to fight cancer. Video linked here. ...

October 4 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data and Mary Crowley Cancer Research have announced a new collaboration with the objective of expanding research options for lung cancer patients. As part of this collaboration, Tempus...

CHICAGO, Sept. 19, 2018 (GLOBE NEWSWIRE) — Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, today announced the launch of its new mobile app, Tempus Labs, which will extend the reach of the Tempus platform, enabling physicians to securely ac...